940 Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.41 |
| 52 Week High | €6.97 |
| 52 Week Low | €2.37 |
| Beta | 0.56 |
| 11 Month Change | 4.15% |
| 3 Month Change | -19.03% |
| 1 Year Change | -36.95% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 940 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -5.0% | -1.3% |
| 1Y | -37.0% | -22.0% | 7.4% |
Return vs Industry: 940 underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 940 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 940 volatility | |
|---|---|
| 940 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 940 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 940's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,329 | Ludwig De Mot | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. It provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. The company was incorporated in 2020 and is based in Paris, France.
Euroapi S.A. Fundamentals Summary
| 940 fundamental statistics | |
|---|---|
| Market cap | €325.61m |
| Earnings (TTM) | -€287.30m |
| Revenue (TTM) | €971.30m |
0.3x
P/S Ratio-1.1x
P/E RatioIs 940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 940 income statement (TTM) | |
|---|---|
| Revenue | €971.30m |
| Cost of Revenue | €805.80m |
| Gross Profit | €165.50m |
| Other Expenses | €452.80m |
| Earnings | -€287.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | -3.02 |
| Gross Margin | 17.04% |
| Net Profit Margin | -29.58% |
| Debt/Equity Ratio | 50.9% |
How did 940 perform over the long term?
See historical performance and comparison